Unilife Corporation Announces Financial Results For Fiscal Year 2014 Second Quarter PR Newswire YORK, Pa., Feb. 3, 2014 YORK, Pa., Feb. 3, 2014 /PRNewswire/ -- Unilife Corporation ("Unilife" or "Company") (NASDAQ:UNIS; ASX: UNS), a developer and supplier of injectable drug delivery systems, today announced its financial results for the quarter ended December 31, 2013, (the second quarter of Fiscal Year 2014). Recent Highlights oIn November 2013, Unilife signed a long-term commercial supply contract withHikma PharmaceuticalsPLC ("Hikma") for the use of Unifill^®prefilled syringes with an initial list of 20 generic injectable drugs. Product sales toHikmawill commence in early calendar 2014, with a minimum 175MM units per year to be purchased following a high-volume ramp program. In addition to product sales,Unilifeexpects to receive $40 millionin upfront and milestone payments over the next two years. Unilife received the first payment of $5 million from Hikma during the second quarter of fiscal year 2014. Additional milestone payments have also been received during the third quarter of fiscal year 2014. oIn November 2013, Unilife signed an agreement withMedImmune, the global biologics arm of AstraZeneca, to customize and supply devices from its platform of wearable injectors for use with several target drug candidates from MedImmune's portfolio.Unilife is receiving regular payments from MedImmune under the contract. oIn December 2013, Unilife signed a contract with a global pharmaceutical company seeking to use Unilife's Ocu-ject™ delivery system to deliver a target injectable therapy into the eye. Revenue under the program is scheduled to commence during the third quarter of fiscal year 2014. oIn December 2013, Unilife signed an agreement with Novartis to supply clinical products from one of its platforms of injectable drug delivery systems for use with a targeted early stage pipeline drug. Unilife began to generate revenue under the Novartis under the program during the second quarter of fiscal year 2014. Additional payments are expected as the program continues this calendar year. oUnilife also continues to receive milestone payments and revenue from other customer programs. This includes $5 million in payments from Sanofi during the first quarter of fiscal year 2014, with an additional $5 million being received during the current third quarter of fiscal year 2014. In total, Unilife has invoiced for more than $20 million since the start of fiscal year 2014, with the majority of that cash having been received since November 2013. Mr. Alan Shortall, CEO of Unilife, commented: "This has been a strong quarter for Unilife, in which momentum continues to build. Many significant new long-term contracts have been signed with leading pharmaceutical companies including Novartis, MedImmune and Hikma. Milestone payments and revenue are increasing as a result of our execution of these and other customer programs. I expect this pace to continue as additional contracts progressively emerge from our large, expanding commercial pipeline." Financial Results for Three Months Ended December 31, 2013 Revenue for the three months ended December 31, 2013, was $3.6 million compared to $0.7 million for the same period in 2012. The Company's net loss for the three months ended December 31, 2013, was $16.3 million, or $0.17 per share, compared to a net loss of $14.6 million, or $0.19 per share, for the same period in 2012. Adjusted net loss for the three months ended December 31, 2013, was $8.3 million, or $0.08 per share, compared to $9.7 million, or $0.12 per share, for the same period in 2012. Adjusted net loss excludes non-cash share-based compensation expense, depreciation and amortization and interest expense. Unilife reported $6.7 million of total cash and cash equivalents, including restricted cash, as of December 31, 2013. This does not include $6.2 million in cash generated under the Company's ATM facility with Cantor Fitzgerald in January 2014. Conference Call Information Management has scheduled a conference call for 4:30 p.m. U.S. EST on Monday, February 3, 2014, (Tuesday, February 4, 2014 at 8:30 a.m. AEDT), to review the Company's financial results, customer partnerships and future outlook. The conference call and accompanying slide presentation will be broadcast over the Internet as a "live" listen-only Webcast. An archive of the presentation and webcast will be available for 30 days after the call. To listen, please go to: http://ir.unilife.com/events.cfm. About Unilife Corporation Unilife Corporation (NASDAQ:UNIS / ASX: UNS) is a U.S. based developer and commercial supplier of injectable drug delivery systems. Unilife's broad portfolio of proprietary technologies includes prefilled syringes with automatic needle retraction, drug reconstitution delivery systems, auto-injectors, wearable injectors, ocular delivery systems and novel systems. Each of these innovative and highly differentiated platforms can be customized to address specific customer, drug and patient requirements. Unilife's global headquarters and state-of-the-art manufacturing facilities are located in York, PA. For more information, please visit www.unilife.com or download the Unilife IRapp on your iPhone, iPad or Android device. Forward-Looking Statements Thispress release contains forward-looking statements. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements.These forward-looking statements are based on management's beliefs and assumptions and on information currently available to our management. Our management believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. We do not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results, events and developments to differ materially from our historical experience and our present expectations or projections. These risks and uncertainties include, but are not limited to, those described in "Item1A. Risk Factors" and elsewhere inourAnnual Report on Form 10-Kand those described from time to time in other reports which we file with the Securities and Exchange Commission. Non-GAAP Financial Measures U.S. securities laws require that when we publish any non-GAAP financial measure, we disclose the reason for using the non-GAAP measure and provide reconciliation to the most directly comparable GAAP measure. The presentation of adjusted net income (loss) and adjusted net income (loss) per share are non-GAAP measures. Adjusted net income (loss) represents net income (loss) calculated in accordance with U.S. GAAP as adjusted for the impact of share-based compensation expense, depreciation and amortization and interest expense. Management believes the presentation of adjusted net income (loss) and adjusted net income (loss) per share provides useful information because these measures enhance its own evaluation, as well as investor's understanding, of the Company's core operating and financial results. Non-GAAP financial measures should be considered in addition to results prepared in accordance with GAAP, but should not be considered a substitute for, or superior to, GAAP results. A reconciliation of net income (loss) to adjusted net income (loss) is included in the attached table. General: UNIS-G Investor Contacts Analyst Investor Contacts (US): Enquiries (Australia) Todd Fromer / Garth Lynn Jeff Carter Russell Pieper KCSA Strategic Westwicke Unilife Communications Partners Corporation P: + 1 212-682-6300 P: + 1 P: + 61 2 8346 6500 415-202-5678 UNILIFE CORPORATION AND SUBSIDIARIES Consolidated Balance Sheets (unaudited) December31,2013 June30,2013 (inthousands,exceptsharedata) Assets Current Assets: Cash and cash equivalents $ $ 4,314 5,736 Restricted cash 2,400 2,400 Accounts receivable 2,748 654 Inventories 55 71 Prepaid expenses and other current assets 337 409 Total current assets 9,854 9,270 Property, plant and equipment, net 45,312 46,106 Goodwill 11,166 11,498 Intangible assets, net 21 23 Other 652 1,504 assets Total assets $ $ 67,005 68,401 Liabilities and Stockholders' Equity Current Liabilities: Accounts payable $ $ 1,785 3,428 Accrued expenses 3,577 2,444 Current portion of long-term debt 5,596 3,826 Deferred revenue — 3,010 Total current liabilities 10,958 12,708 Long-term debt, less current portion 19,560 20,045 Deferred revenue 10,068 50 Total liabilities 40,586 32,803 Stockholders' Equity: Preferred stock, $0.01 par value, 50,000,000 shares authorized as of December31, 2013; — — none issued or outstanding as of December31, 2013 and June30, 2013 Common stock, $0.01 par value, 250,000,000 shares authorized as of December31, 2013; 100,787,182 and 95,602,558 shares issued, and 100,758,512 and 95,573,888 shares 1,008 956 outstanding as of December31, 2013 and June30, 2013, respectively Additional paid-in-capital 286,735 268,157 Accumulated deficit (263,359) (235,832 ) Accumulated other comprehensive income 2,175 2,457 Treasury stock, at cost, 28,670 shares as of December31, 2013 and June30, 2013, (140 ) (140 ) respectively Total stockholders' equity 26,419 35,598 Total liabilities and stockholders' equity $ $ 67,005 68,401 UNILIFE CORPORATION AND SUBSIDIARIES Consolidated Statements of Operations and Comprehensive Loss (unaudited) Three Months Ended Six Months Ended December 31, December 31, 2013 2012 2013 2012 (in thousands, except per share data) Revenue $ $ $ $ 3,573 699 6,760 1,391 Cost of product sales — 22 — 81 Gross profit 3,573 677 6,760 1,310 Operating expenses: Research and development 7,807 4,994 14,206 9,732 Selling, general and 6,703 8,327 13,223 14,904 administrative Depreciation and amortization 1,000 1,365 2,042 2,588 Total operating expenses 15,510 14,686 29,471 27,224 Operating loss (11,937) (14,009) (22,711) (25,914) Interest expense 4,351 645 4,831 1,261 Interest income (5) (14) (11) (38) Other income, net — — (4) — Net loss (16,283) (14,640) (27,527) (27,137) Net loss per share: Basic and diluted net loss per $ $ $ $ share (0.17) (0.19) (0.29) (0.35) UNILIFE CORPORATION AND SUBSIDIARIES Reconciliation of Non-GAAP Measure (unaudited) Three Months Ended Six Months Ended December 31, December 31, 2013 2012 2013 2012 (in thousands, except per share data) Net loss $ $ $ $ (16,283) (14,640) (27,527) (27,137) Share-based compensation 2,635 2,963 5,271 4,518 expense Depreciation and amortization 1,000 1,365 2,042 2,588 Interest expense 4,351 645 4,831 1,261 Adjusted net loss $ $ $ $ (18,770) (8,297) (9,667) (15,383) Adjusted net loss per share - $ $ $ $ diluted (0.08) (0.12) (0.16) (0.24) SOURCE Unilife Corporation Website: http://www.unilife.com
Unilife Corporation Announces Financial Results For Fiscal Year 2014 Second Quarter
Press spacebar to pause and continue. Press esc to stop.